Hims & Hers Health (NYSE:HIMS) Stock Price Down 2.1% - Time to Sell?

Key Points

• Hims & Hers Health shares fell 2.1% to $43.63, with trading volume down significantly at 5.6 million shares, which is an 83% decline from the average.
• Analysts have downgraded the stock, with Zacks Research moving it from a "strong-buy" to a "hold," and the consensus price target is set at $38.92.
• The company recently reported earnings of $0.17 per share, missing the consensus estimate, but demonstrated a 72.6% year-over-year revenue growth with total revenue at $544.83 million.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) were down 2.1% on Monday . The company traded as low as $43.14 and last traded at $43.63. Approximately 5,628,236 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 33,544,695 shares. The stock had previously closed at $44.57.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HIMS shares. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Truist Financial cut their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Down 2.3%

The firm has a market capitalization of $9.84 billion, a PE ratio of 54.41, a PEG ratio of 3.01 and a beta of 2.08. The company has a fifty day simple moving average of $51.71 and a two-hundred day simple moving average of $45.85. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. Hims & Hers Health's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Michael Chi sold 2,100 shares of the company's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider directly owned 278,654 shares in the company, valued at $16,028,178.08. This represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $51.64, for a total value of $132,818.08. Following the sale, the insider owned 153,021 shares of the company's stock, valued at $7,902,004.44. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,396,090 shares of company stock valued at $71,927,627. Company insiders own 17.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $29,000. Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after acquiring an additional 600 shares during the last quarter. Finally, Spire Wealth Management purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $42,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.